Following the release of its fiscal Q1 2020 earnings report on Tuesday (August 27), Canopy Rivers (TSXV:RIV,OTC Pink:CNPOF) earned a glowing review from CIBC Capital Markets.

John Zamparo, equity research analyst with CIBC Capital Markets, reaffirmed that the Canadian company remains his top pick in the sector and assigned a 12 to 18 month price target of C$7.

The cannabis company, an investment division launched by Canopy Growth (NYSE:CGC,TSX:WEED), reported a net loss of C$2.9 million for its most recent quarter.

The analyst said he has rated the stock an “outperformer” because of the company’s approach when it comes to capital allocation, its supply contracts and its valuation, which he said is at an all-time low.

Zamparo noted that, despite the third straight monthly double-digit increase in sales for the cannabis space, there’s been a drop in the performance for some of the players. To explain why this is, the analyst said, “(The industry has) rarely traded on fundamentals.”

Canopy Rivers informed investors it expects to see continuing losses due to the development of its investments across the global cannabis market.

“As these equity method investees continue to ramp-up operationally over the coming quarters, management expects to continue to recognize its share of net losses during the remainder of the fiscal year,” the company said in a statement.

Narbe Alexandrian, president and CEO of the firm, also highlighted the development of its investee PharmHouse, which signed a supply agreement with Canopy Growth in May.

Despite its losses, Canopy Rivers CFO Eddie Lucarelli said the company holds strong potential to maintain its position moving forward. In a statement, he said:

“While some of our financial results are linked to the public markets and therefore subject to volatility, we believe that several factors — including significant business catalysts within our portfolio, operational improvements that translate into increased production at our royalty investees, and an operating expense base that is low by cannabis sector standards — position us well to create value for our shareholders in the long term.”

Shares of Canopy Rivers fell after its results release. The decline of just over 5 percent resulted in the company opening Wednesday’s trading session at a price per share of C$2.22. As of 3:48 p.m. EDT on Wednesday, shares of Canopy Rivers were trading at C$2.20, indicating a drop of almost 1 percent.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less